Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
…
109,725€
-1,01%
Echtzeit-Aktienkurs Sarepta Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Sarepta Therapeutics Inc. Aktie
Sarepta Therapeutics: Another Hold Call Ahead Of Some Key Catalysts
…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
The upcoming regulatory decision on its latest drug could be big.…
UBS raises Sarepta Therapeutics shares target on label outlook By Investing.com
UBS raises Sarepta Therapeutics shares target on label outlook…
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2023.…
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
…
Is It Too Late to Buy Sarepta Therapeutics Stock?
The companys hyperfocus on its core area could continue to be highly lucrative.…
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.…
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Its always tough to be compared to a giant.…
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
…
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
One pundit feels there is solid potential in one of the companys more recently approved drugs.…
Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
…
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering By Investing.com
Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering…
Sarepta Therapeutics provides Q4 and FY forecast
…
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market.…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns
…
Is Sarepta Therapeutics Stock a Bad-News Buy? @themotleyfool #stocks $SRPT
Analysts still expect some sizable returns from the stock.…
Is Sarepta Therapeutics Stock a Bad-News Buy?
Analysts still expect some sizable returns from the stock.…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2023.…
SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues…
Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript
…
Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M
…
Sarepta Therapeutics Q3 2023 Earnings Preview
…
Sarepta Therapeutics, Petmed Express among healthcare movers
…
Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades By Investing.com
Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades…
: Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
Company plans to seek label expansion for Duchenne muscular dystrophy treatment…
How to Invest in Genetics (Updated 2023)
Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…
Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy
…
Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester
Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
An upcoming data readout could fuel another rally in the biotechs shares....…
Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 1.092.429$
Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-14...…
Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 2.559.272$
Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-11...…
Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 3.701.067$
Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-10...…
Insiderhandel: Aufsichtsrat verkauft Aktien von Sarepta Therapeutics im Wert von 1.600.800$
Wigzell, Hans Lennart Rudolf - Aufsichtsrat - Tag der Transaktion: 2023-08-04...…
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2023....…
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 85.71% and 1.21%, respectively, for the quarter ended June 2023. Do…
Sarepta Therapeutics Q2 Loss Decreases, beats estimates
WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) revealed Loss for second quarter that decreased from the same period last year and…
Sarepta (SRPT) Sells Priority Review Voucher for $102M
Sarepta (SRPT) sells its priority review voucher that was awarded following the FDAs approval to Elevidys gene therapy for treating…
Sarepta raises $102M from selling priority review voucher
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sarepta Therapeutics completes sale of priority review voucher for $102 million
Sarepta Therapeutics Inc. SRPT said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for…
Sarepta slumps as concerns emerge around upcoming gene therapy data
...June 23 (Reuters) - Sarepta Therapeutics shares
slumped 11% on Friday......…
What 25 Analyst Ratings Have To Say About Sarepta Therapeutics
Latest Ratings for SRPT
DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022RBC CapitalMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight
View…
FDA OKs Elevidys As First Gene Therapy To Treat Duchenne Muscular Dystrophy
WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. announced Friday that the U.S. Food and Drug Administration or FDA has accelerated approval…